$2.27
6.57% yesterday
Nasdaq, Oct 15, 10:05 pm CET
ISIN
US47010C3007
Symbol
JAGX

Jaguar Health, Inc. Stock price

$2.27
+0.30 15.23% 1M
-2.84 55.58% 6M
-22.98 91.01% YTD
-26.73 92.17% 1Y
-17,716.48 99.99% 3Y
-103,542.73 100.00% 5Y
-893,024,997.73 100.00% 10Y
-2,402,662,497.73 100.00% 20Y
Nasdaq, Closing price Wed, Oct 15 2025
+0.14 6.57%
ISIN
US47010C3007
Symbol
JAGX
Industry

Key metrics

Basic
Market capitalization
$8.4m
Enterprise Value
$35.5m
Net debt
$27.1m
Cash
$2.2m
Shares outstanding
1.5m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
0.7 | 0.6
EV/Sales
3.0 | 2.5
EV/FCF
negative
P/B
1.1
Financial Health
Equity Ratio
18.3%
Return on Equity
-394.0%
ROCE
-172.4%
ROIC
-
Debt/Equity
3.7
Financials (TTM | estimate)
Revenue
$11.8m | $14.3m
EBITDA
$-30.9m | $-23.7m
EBIT
$-32.8m | $-28.5m
Net Income
$-40.7m | $-37.2m
Free Cash Flow
$-27.7m
Growth (TTM | estimate)
Revenue
15.9% | 22.4%
EBITDA
-5.1% | 18.2%
EBIT
-4.7% | 7.5%
Net Income
-14.0% | 3.5%
Free Cash Flow
6.1%
Margin (TTM | estimate)
Gross
81.9%
EBITDA
-262.0% | -
EBIT
-278.1%
Net
-344.2% | -259.7%
Free Cash Flow
-234.3%
More
EPS
$-40.1
FCF per Share
$-18.1
Short interest
2.2%
Employees
49
Rev per Employee
$240.0k
Show more

Is Jaguar Health, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

Jaguar Health, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Jaguar Health, Inc. forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Jaguar Health, Inc. forecast:

Buy
86%
Hold
14%

Financial data from Jaguar Health, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
12 12
16% 16%
100%
- Direct Costs 2.14 2.14
4% 4%
18%
9.67 9.67
19% 19%
82%
- Selling and Administrative Expenses 27 27
23% 23%
228%
- Research and Development Expense 16 16
11% 11%
132%
-31 -31
5% 5%
-262%
- Depreciation and Amortization 1.91 1.91
2% 2%
16%
EBIT (Operating Income) EBIT -33 -33
5% 5%
-278%
Net Profit -41 -41
14% 14%
-344%

In millions USD.

Don't miss a Thing! We will send you all news about Jaguar Health, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Jaguar Health, Inc. Stock News

Neutral
Accesswire
10 days ago
Additional update: Results of ongoing investigator-initiated proof-of-concept trial in United Arab Emirates (UAE) demonstrate further reduction of total parenteral support (PS) (comprised of total parenteral nutrition and supplementary IV fluids) of approximately 37% SAN FRANCISCO, CA / ACCESS Newswire / October 6, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family company Napo Pharmaceut...
Neutral
Accesswire
16 days ago
The two programs are being conducted under separate Single-Patient Investigational New Drug (sIND) applications in the United States SAN FRANCISCO, CA / ACCESS Newswire / September 30, 2025 / Jaguar Health (NASDAQ:JAGX) today announced that Jaguar family company Napo Pharmaceuticals (Napo) is providing the company's novel crofelemer powder for oral solution for use in two expanded access progra...
Neutral
Accesswire
21 days ago
Company strategy: In discussions with multiple potential animal health company partners to expand the indication and commercialize Canalevia for treatment of general diarrhea globally SAN FRANCISCO, CA / ACCESS Newswire / September 25, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar"), under its Jaguar Animal Health tradename for the veterinary market, today announced that it has received not...
More Jaguar Health, Inc. News

Company Profile

Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. Its products include Canalevia, Equilevia, and Neonorm. It operates through the Human Health and Animal Health segments. The Human Health segment manufactures human products and the ongoing advertising of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The Animal Health segment commercializes prescription and non-prescription products for companion and production animals. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA.

Head office United States
CEO Lisa Conte
Employees 49
Founded 2013
Website jaguar.health

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today